Clinical trial Recruiting at 1 site Interventional Ages 6 and up

Circadian rhythm changes in people with CAPS

Official title: Identification of Circadian Rhythm Deregulation in Patients With Cryopyrin-associated Periodic Syndrome (CAPS)

Run by Hospices Civils de Lyon · NCT06544018 · Data updated 2026-11-12

This project will test whether people with CAPS have altered circadian rhythms by measuring sleep timing, saliva melatonin, and NLRP3 genetics and comparing them to healthy household members.

Quick facts

Study typeInterventional
Ages6 Years and up
SexAll
Enrollment30 (estimated)
SponsorHospices Civils de Lyon
Academic / other
Locations6 sites (Bron and 5 other locations)
StatusRecruiting
StartedFebruary 25, 2026
Main results expectedFebruary 25, 2029
Study endsFebruary 25, 2029
Registry record updatedFebruary 27, 2026
Trial IDNCT06544018 on ClinicalTrials.gov

Is this trial a fit for you?

Likely a good fit

Ideal candidates are patients aged 6 or older with genetically confirmed CAPS (NLRP3), weight ≥25 kg and consent, together with healthy household members of similar age and weight willing to undergo saliva sampling and genetic testing.

Probably not a fit

Patients with chronic sleep disorders requiring medication or those without an NLRP3 mutation are unlikely to gain direct benefit from participation.

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This interventional protocol compares circadian biology in patients with CAPS (confirmed by NLRP3 genetic analysis) to healthy household controls. Participants aged 6 and older provide saliva samples for melatonin measurement, complete sleep and symptom questionnaires including the AIDAI score, and undergo circadian rhythm monitoring. Genetic analysis of NLRP3 will confirm diagnosis and permit exploration of links between genotype and circadian markers. Subjects with chronic medicated sleep disorders are excluded to reduce confounding.

Why it matters

Potential benefit: If successful, the work could reveal circadian disruption as a treatable feature of CAPS and suggest timing-based or anti-inflammasome strategies to reduce symptoms.

How similar studies have gone: Preclinical and clinical research links circadian regulation to NLRP3 inflammasome activity, but circadian profiling specifically in genetically confirmed CAPS patients is novel and not yet established.

Who can join: the full rules

Show full inclusion / exclusion criteria
---Inclusion Criteria:

Patient with CAPS group :

* Patients aged 6 and over
* Participant with CAPS confirmed by NLRP3 genetic analysis
* Weight greater than or equal to 25 Kg
* Parents/guardians who have been informed of the study and have signed a consent form.
* Patient affiliated to a social security scheme

Control group (healthy participant):

* Participant aged 6 and over
* Weight greater than or equal to 25 Kg
* Participant living in the same household as a subject with CAPS genetically confirmed by NLRP3 analysis and included in the protocol
* Participant with no CAPS (a priori) who consents to NLRP3 genetic analysis
* Parents/guardians who have been informed of the study and have signed a consent form.
* Participant who has been informed of the study and has agreed to take part
* Participant affiliated to a social security scheme

  * Exclusion Criteria :

Patient with CAPS group :

* Patients with chronic sleep disorders (narcolepsy, hypersomnia) requiring medication (sleeping pills, melatonin).
* Patients with sleep apnea syndrome
* Patients working regular night shifts or alternating day and night shifts
* Pregnant or breast-feeding women
* Parents with an infant under 6 months of age
* Patient participating in another interventional drug study
* Deprivation of civil rights (curators, guardianship, safeguard of justice)

Control group (healthy participant):

* Participants with a chronic illness (ALD beneficiaries)
* Participants with chronic sleep disorders (narcolepsy, hypersomnia) requiring medication (sleeping pills, melatonin)
* Participants working regular night shifts or alternating day and night shifts
* Pregnant or breast-feeding women
* Parents with an infant under 6 months of age
* Participant participating in another interventional drug study
* Deprivation of civil rights (curators, guardianship, safeguard of justice)

Where it's running

  • Hôpital Femme-Mère-Enfant (HCL)
    Bron, France
    Recruiting
  • Hôpital Claude Huriez (CHU de Lille)
    Lille, France
    Not yet recruiting
  • Hôpital de la Croix-Rousse (HCL)
    Lyon, France
    Not yet recruiting
  • Hôpital Edouard Herriot (HCL)
    Lyon, France
    Not yet recruiting
  • Hôpital Tenon (AP-HP)
    Paris, France
    Not yet recruiting
  • Hôpital Kremlin-Bicêtre (AP-HP)
    Paris, France
    Not yet recruiting

Study contacts

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

How to take part

  1. Review the eligibility criteria above with your treating physician.
  2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
  3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.